Clinical-stage Biotechnology Company Announces Patent Licensing Agreement With Research Firm

Clearmind Medicine’s recent announcement marks the beginning of a pivotal phase in its development trajectory..

Welcome to a new era in the treatment of post-traumatic stress disorder (PTSD) and other mental health conditions, Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0), a clinical-stage biotech innovator at the forefront of psychedelic-derived therapeutic development, has announced a landmark exclusive patent licensing agreement with Yissum Research Develo…